Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17928
Title: Prospective analysis of hydrogel spacer for patients with prostate cancer undergoing radiotherapy.
Authors: Chao, Michael;Ho, Huong;Chan, Yee;Tan, Alwin;Pham, Trung;Bolton, Damien M;Troy, Andrew J;Temelcos, Catherine;Sengupta, Shomik;McMillan, Kevin;Cham, Chee Wee;Liu, Madalena;Ding, Wei;Subramanian, Brindha;Wasiak, Jason;Lim Joon, Daryl;Spencer, Sandra;Lawrenstchuk, Nathan
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Genesis Cancer Care Victoria, Ringwood East, Vic, Australia..
Ringwood Private Hospital, Ringwood East, Vic, Australia..
The Valley Private Hospital, Mulgrave, Vic, Australia..
St Vincent's Hospital, Fitzroy, Vic, Australia..
Melbourne University; Eastern Health Clinical School, Monash University, Clayton, Vic, Australia..
Ringwood Private Hospital, Ringwood East, Vic, Australia
The Bays Hospital, Mornington, Vic, Australia
University of Melbourne, Melbourne, Vic, Australia
Issue Date: 9-Mar-2018
EDate: 2018-03-09
Citation: BJU international 2018; online first: 9 March
Abstract: To report on the dosimetric benefits and late toxicity outcomes after injection of hydrogel spacer (HS) between the prostate and rectum for patients treated with prostate radiotherapy (RT). In all, 76 patients with a clinical stage of T1-T3a prostate cancer underwent general anaesthesia for fiducial marker insertion plus injection of the HS into the perirectal space before intensity-modulated RT (IMRT) or volumetric-modulated arc RT (VMAT). HS safety, dosimetric benefits, and the immediate- to long-term effects of gastrointestinal (GI) toxicity were assessed. There were no postoperative complications reported. The mean (range) prostate size was 66.0 (25.0-187.0) mm. Rectal dose volume parameters were observed and the volume of rectum receiving 70 Gy (rV70 ), 75 Gy (rV75 ) and 78 Gy (rV78 ) was 7.8%, 3.6% and 0.4%, respectively. In all, 21% of patients (16/76) developed acute Grade 1 GI toxicities, but all were resolved completely by 3 months after treatment; whilst, 3% of patients (2/76) developed late Grade 1 GI toxicities. No patients had acute or late Grade ≥2 GI toxicities. Injection of HS resulted in a reduction of irradiated rectal dose volumes along with minimal GI toxicities, irrespective of prostate size.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17928
DOI: 10.1111/bju.14192
ORCID: 0000-0002-8212-4220
0000-0003-3357-1216
0000-0001-9681-2174
0000-0001-8553-5618
0000-0002-5145-6783
PubMed URL: 29520983
Type: Journal Article
Subjects: #PCSM
#ProstateCancer
hydrogel spacer
intensity-modulated RT
volumetric-modulated arc RT
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.